Skip to main content

Advertisement

SpringerLink
Log in

Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

We investigated the relationship between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and vascular endothelial growth factor (VEGF) and renal function, and correlations between vitreous sRAGE levels and proliferative diabetic retinopathy (PDR) activity.

Methods

We examined 33 eyes from 33 patients with diabetes mellitus who underwent a vitrectomy (eight patients in the non-PDR [NPDR] group and 25 in the PDR group). Serum creatinine levels and estimated glomerular filtration rate (eGFR) were measured and classified according to the chronic kidney disease (CKD)-staging method. Enzyme-linked immunosorbent assay (ELISA) was performed to quantify vitreous sRAGE and VEGF levels.

Results

Vitreous sRAGE levels were significantly higher in PDR group compared to NPDR group (p = 0.00003). Vitreous sRAGE levels were significantly higher in patients with CKD stage 5 (end-stage renal failure or hemodialysis) than in patients with CKD stage 1 or 2 (p < 0.01) and 3 or 4 (p < 0.05), and were significantly correlated with eGFR (r = − 0.490, p = 0.007) and creatinine levels (r = 0.484, p = 0.006). Within the PDR group, patients with low (<27 pg/mL) sRAGE levels required repeat vitreous surgeries for early postoperative vitreous hemorrhage significantly more frequently than those with high (≥27 pg/mL) sRAGE levels (p = 0.0067).

Conclusions

Vitreous sRAGE levels were significantly correlated with renal function, and low vitreous sRAGE levels in patients with PDR were associated with postoperative vitreous hemorrhage. Vitreous sRAGE may be a useful biomarker for renal dysfunction associated with diabetic retinopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention (2014) National Diabetes Statistics Report, 2014. Atlanta: US Department of Health and Human Services. http://www.diabetes.org/diabetes-basics/statistics/. Accessed 2 October 2014

  2. Lee WJ, Sobrin L, Kang MH, Seong M, Kim YJ, Yi JH, Miller JW, Cho HY (2014) Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye 28:1119–1125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Matsuo T (2006) Disappearance of diabetic macular hard exudates after hemodialysis introduction. Acta Med Okayama 60:201–205

    PubMed  Google Scholar 

  4. Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101

    Article  CAS  PubMed  Google Scholar 

  5. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299

    Article  CAS  PubMed  Google Scholar 

  6. Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi M, Yamamoto H (2007) Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 77:S30–S40

    Article  CAS  PubMed  Google Scholar 

  7. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGE) theory in diabetic complication. Curr Mol Med 6:351–358

    Article  CAS  PubMed  Google Scholar 

  8. Ai J, Liu Y, Sun JH (2013) Advanced glycation end-products stimulate basic fibroblast growth factor expression in cultured Müller cells. Mol Med Rep 7:16–20

    Article  CAS  PubMed  Google Scholar 

  9. Zong H, Ward A, Madden A, Yong PH, Limb GA, Curis TM, Stitt AW (2010) Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products(RAGE). Diabetologia 53:2656–2666

    Article  CAS  PubMed  Google Scholar 

  10. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48:858–865

    Article  PubMed  Google Scholar 

  11. Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47:406–411

    Article  PubMed  Google Scholar 

  12. Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026

    Article  PubMed  Google Scholar 

  13. Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B (2015) Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant 30:84–91

    Article  CAS  PubMed  Google Scholar 

  14. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis. Diabetes Care 32:1218–1220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler ThrombVasc Biol 25:1032–1037

    Article  CAS  Google Scholar 

  16. Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC (2013) sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62:2116–2121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682

    Article  CAS  PubMed  Google Scholar 

  18. Kidney disease: Improving global outcomes (KDIGO) CKD work group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150

    Article  Google Scholar 

  19. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-CE, Tsang TC, Stern D (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987–14997

    CAS  PubMed  Google Scholar 

  20. Takagi H, King GL, Aiello LP (1996) Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45:1016–1023

    Article  CAS  PubMed  Google Scholar 

  21. Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807–815

    Article  CAS  PubMed  Google Scholar 

  22. El-Asrar AM, Nawaz MI, Kangave D, Geboes K, Ola MS, Ahmad S, Al-Shabrawey M (2011) High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis 17:1829–1838

    PubMed  PubMed Central  Google Scholar 

  23. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916–2924

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would particularly like to thank Dr. Noriko Inada for her insightful comments and suggestions. We also wish to thank Drs. Akira Hirose, Kensuke Haruyama, Kaori Sekimoto, Tetsuri Sugimoto, and Maki Shoji for their assistance in collecting vitreous samples and performing ophthalmological examinations. We also thank Ms. Akiko Tomioka (Ishimori) for her excellent technical assistance. We presented the contents of this article at the 69th Annual Congress of Japan Clinical Ophthalmology on October 22, 2015. This research did not receive any specific grant funding from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Diabetes Center, Tokyo Women’s Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Makiko Katagiri & Shigehiko Kitano

  2. Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan

    Jun Shoji

  3. Department of Ophthalmology, The University of Tokyo, Tokyo, Japan

    Satoshi Kato

  4. Department of Medicine, Diabetes Center, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

    Yasuko Uchigata

Authors
  1. Makiko Katagiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigehiko Kitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuko Uchigata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makiko Katagiri.

Ethics declarations

Conflict of interest

The authors have no conflict of interest directly relevant to the content of this article. Author J.S. has received a speaker honorarium from Santen Pharmaceutical and Alcon Japan. Author S.K. has received a speaker honorarium from Novartis, Bayer, Alcon Japan and Topcon. Author Y.U. has received a speaker honorarium from Novo Nordisk Pharma, Sanofi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Eli Lilly Japan, and MSD. This author has also received research grants from Novartis, Astellas, Pfizer, Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Kyowa Hakko Kirin, Alcon Japan, Otsuka Pharmaceutical, NIPRO, Eli Lilly Japan, Kowa, Eisai, Takeda Pharmaceutical, Sanofi, Mitsubishi Tanabe Pharma, MSD, Ono pharmaceutical, Novo Nordisk Pharma, Terumo, Sumitomo Dainippon Pharma, and Daiichi Sankyo.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katagiri, M., Shoji, J., Kato, S. et al. Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy. Int Ophthalmol 37, 1247–1255 (2017). https://doi.org/10.1007/s10792-016-0389-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-016-0389-y

Keywords

Search

Navigation